Literature DB >> 28362648

Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients.

Soundarya N Selvam1, Lara J Casey, Mackenzie L Bowman, Lindsey G Hawke, Avery J Longmore, Jeffrey Mewburn, Mark L Ormiston, Stephen L Archer, Donald H Maurice, Paula James.   

Abstract

: Bleeding associated with angiodysplasia is a common, often intractable complication in patients with von Willebrand disease (VWD). von Willebrand factor (VWF), the protein deficient or defective in VWD, is a negative regulator of angiogenesis, which may explain the pathologic blood vessel growth in VWD. This study explores the normal range of angiogenesis in blood outgrowth endothelial cells (BOECs) derived from healthy donors and compares this to angiogenesis in BOECs from VWD patients of all types and subtypes. BOECs were assessed for VWF and angiopoietin-2 (Ang-2) gene expression, secretion, and storage. To explore angiogenic potential, we characterized cellular proliferation, matrix protein adhesion, migration, and tubule formation. We found great angiogenic variability in VWD BOECs with respect to each of the angiogenesis parameters. However, type 1 and 3 VWD BOECs had higher Ang-2 secretion associated with impaired endothelial cell migration velocity and enhanced directionality. Type 2A and 2B BOECs were the most proliferative and multiple VWD BOECs had impaired tubule formation in Matrigel. This study highlights the angiogenic variability in BOECs derived from VWD patients. Abnormal cell proliferation, migration, and increased Ang-2 secretion are common features of VWD BOECs. Despite the many abnormalities of VWD BOECs, significant heterogeneity among individual VWD phenotypes precludes a simple description of relationship between VWD type and in vitro surrogates for angiodysplasia.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28362648      PMCID: PMC5960581          DOI: 10.1097/MBC.0000000000000635

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  30 in total

1.  Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites.

Authors:  G E Davis
Journal:  Biochem Biophys Res Commun       Date:  1992-02-14       Impact factor: 3.575

Review 2.  Endothelial cell migration during angiogenesis.

Authors:  Laurent Lamalice; Fabrice Le Boeuf; Jacques Huot
Journal:  Circ Res       Date:  2007-03-30       Impact factor: 17.367

3.  Telangiectasia and von Willebrand's disease in two families.

Authors:  C L Conlon; R S Weinger; P L Cimo; J L Moake; J D Olson
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

4.  Early transfusion of factor VIII/von Willebrand factor concentrates seems to be effective in the treatment of gastrointestinal bleeding in patients with von Willebrand type III disease.

Authors:  E Zanon; F Vianello; A Casonato; A Girolami
Journal:  Haemophilia       Date:  2001-09       Impact factor: 4.287

5.  A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro.

Authors:  Cheen Peen Khoo; Kingsley Micklem; Suzanne M Watt
Journal:  Tissue Eng Part C Methods       Date:  2011-06-08       Impact factor: 3.056

6.  Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease.

Authors:  Jiong-Wei Wang; Eveline A M Bouwens; Maria Carolina Pintao; Jan Voorberg; Huma Safdar; Karine M Valentijn; Hetty C de Boer; Koen Mertens; Pieter H Reitsma; Jeroen Eikenboom
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

7.  Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.

Authors:  M Bowman; G Mundell; J Grabell; W M Hopman; D Rapson; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2008-10-04       Impact factor: 5.824

8.  Case report: recurrent hematuria and hematospermia due to prostatic telangiectasia in classic von Willebrand's disease.

Authors:  R A Lemesh
Journal:  Am J Med Sci       Date:  1993-07       Impact factor: 2.378

9.  Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.

Authors:  Sascha David; Philipp Kümpers; Alexander Lukasz; Jan T Kielstein; Hermann Haller; Danilo Fliser
Journal:  J Hypertens       Date:  2009-08       Impact factor: 4.844

10.  Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.

Authors:  Richard D Starke; Koralia E Paschalaki; Clare E F Dyer; Kimberly J Harrison-Lavoie; Jacqueline A Cutler; Thomas A J McKinnon; Carolyn M Millar; Daniel F Cutler; Mike A Laffan; Anna M Randi
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

View more
  13 in total

Review 1.  Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians.

Authors:  Radha Mehta; Muhammad Athar; Sameh Girgis; Atif Hassan; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

2.  Human Endothelial Colony-Forming Cells.

Authors:  Juan M Melero-Martin
Journal:  Cold Spring Harb Perspect Med       Date:  2022-04-04       Impact factor: 5.159

3.  von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells.

Authors:  Mackenzie Bowman; Lara Casey; Soundarya N Selvam; Patricia D A Lima; Orla Rawley; Megan Hinds; Angie Tuttle; Julie Grabell; Alfonso Iorio; Irwin Walker; David Lillicrap; Paula James
Journal:  J Thromb Haemost       Date:  2022-05-03       Impact factor: 16.036

Review 4.  von Willebrand factor regulation of blood vessel formation.

Authors:  Anna M Randi; Koval E Smith; Giancarlo Castaman
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

5.  Characterization of a Porcine Model for Von Willebrand Disease Type 1 and 3 Regarding Expression of Angiogenic Mediators in the Nonpregnant Female Reproductive Tract.

Authors:  Hanna Allerkamp; Stefanie Lehner; Mahnaz Ekhlasi-Hundrieser; Carsten Detering; Christiane Pfarrer; Mario von Depka Prondzinski
Journal:  Comp Med       Date:  2019-09-16       Impact factor: 0.982

6.  Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.

Authors:  Robert Ariens; Cecilia Becattini; Markus Bender; Wolfgang Bergmeier; Elisabetta Castoldi; Katrien Devreese; Martin Ellis; David Gailani; Vera Ignjatovic; Paula D James; Steven Kerrigan; Michele Lambert; Lai Heng Lee; Marcel Levi; Norma Maugeri; Joost Meijers; Juan Melero-Martin; Alan D Michelson; Federico Mingozzi; Keith Neeves; Heyu Ni; Anna-Karin Olsson; Zoltán Prohászka; Marie Ranson; Nicoletta Riva; Yotis Senis; Cornelia H van Ommen; Douglas E Vaughan; John Weisel
Journal:  Res Pract Thromb Haemost       Date:  2020-07-12

Review 7.  Recent Advances in Endothelial Colony Forming Cells Toward Their Use in Clinical Translation.

Authors:  Koralia E Paschalaki; Anna M Randi
Journal:  Front Med (Lausanne)       Date:  2018-10-23

8.  Variability of von Willebrand factor-related parameters in endothelial colony forming cells.

Authors:  Annika de Jong; Ester Weijers; Richard Dirven; Suzan de Boer; Jasmin Streur; Jeroen Eikenboom
Journal:  J Thromb Haemost       Date:  2019-07-22       Impact factor: 5.824

9.  Alternative trafficking of Weibel-Palade body proteins in CRISPR/Cas9-engineered von Willebrand factor-deficient blood outgrowth endothelial cells.

Authors:  Maaike Schillemans; Marije Kat; Jurjen Westeneng; Anastasia Gangaev; Menno Hofman; Benjamin Nota; Floris P J van Alphen; Martin de Boer; Maartje van den Biggelaar; Coert Margadant; Jan Voorberg; Ruben Bierings
Journal:  Res Pract Thromb Haemost       Date:  2019-08-01

Review 10.  Von Willebrand Disease: From In Vivo to In Vitro Disease Models.

Authors:  Suzan de Boer; Jeroen Eikenboom
Journal:  Hemasphere       Date:  2019-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.